Jamison Private Wealth Management Inc. Has $1.92 Million Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Jamison Private Wealth Management Inc. raised its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,908 shares of the medical equipment provider’s stock after acquiring an additional 232 shares during the quarter. Jamison Private Wealth Management Inc.’s holdings in Intuitive Surgical were worth $1,920,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Creekmur Asset Management LLC increased its stake in Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 42 shares during the last quarter. Ridgewood Investments LLC bought a new stake in Intuitive Surgical during the second quarter worth about $26,000. Delos Wealth Advisors LLC raised its holdings in Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 57 shares in the last quarter. LRI Investments LLC acquired a new position in Intuitive Surgical during the first quarter valued at approximately $30,000. Finally, LGT Financial Advisors LLC grew its stake in Intuitive Surgical by 415.4% in the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 54 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling

In other news, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the sale, the director now directly owns 12,275 shares in the company, valued at approximately $5,441,507.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $490.28, for a total value of $220,626.00. Following the transaction, the director now directly owns 821 shares of the company’s stock, valued at $402,519.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the sale, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock valued at $25,528,753 over the last 90 days. 0.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ISRG. Truist Financial increased their price objective on Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a report on Monday. Raymond James lifted their price objective on shares of Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a research report on Monday. Robert W. Baird upped their target price on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a report on Friday, July 19th. Stifel Nicolaus lifted their price target on Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a report on Friday, July 19th. Finally, Evercore ISI upped their price objective on Intuitive Surgical from $410.00 to $475.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $467.55.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $478.47 on Wednesday. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $496.48. The stock has a market cap of $169.71 billion, a PE ratio of 86.37, a PEG ratio of 5.40 and a beta of 1.39. The firm has a 50-day moving average of $481.94 and a 200-day moving average of $436.37.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter in the prior year, the business posted $1.18 EPS. The business’s revenue was up 14.5% compared to the same quarter last year. Equities research analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.